References
- Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39(Suppl 1):S32–S37. doi:10.1086/383050
- Fry WA, Phillips JL, Menck HR. Ten‐year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999;86:1867–1876. doi:10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9
- Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with neutropenic fever in adult cancer patients. Cancer. 2006;106:2258–2266. doi:10.1002/cncr.21847
- Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother. 2014;58(7):3799–3803. doi:10.1128/AAC.02561-14
- Tam CS, O’reilly M, Andresen D, et al. Use of empiric antimicrobial therapy in neutropenic fever. Intern Med J. 2011;41:90–101. doi:10.1111/j.1445-5994.2010.02340.x
- Cancer Institute NSW. Immediate management of neutropenic fever. eviQ Cancer TreatmentsOnline; [ cited February 21, 2019]. Available from: https://www.eviq.org.au/clinical-resources/oncological-emergencies/123-immediatemanagement-of-neutropenic-fever#. Accessed November 25, 2021.
- Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with neutropenic fever. BMC Health Serv Res. 2014;14:162. doi:10.1186/1472-6963-14-162
- Skiba R, Sikotra N, Ball T. Management of neutropenic fever in a private hospital oncology unit. Intern Med J. 2020;50:959–964. doi:10.1111/imj.14464
- Clarke R, Warnick J, Stretton K, Littlewood T. Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit. BJHaem. 2011;153:773–779. doi:10.1111/j.1365-2141.2011.08693.x
- Zimmer A, Freifeld A. Optimal management of neutropenic fever in patients with cancer. J Oncol Pract. 2019;1:19–24. doi:10.1200/JOP.18.00269
- Keng MK, Thallner EA, Elson P, et al. Reducing time to antibiotic administration for febrile neutropenia in the emergency department. J Oncol Pract. 2015;11(6):450–455. doi:10.1200/JOP.2014.002733
- Sammut SJ, Mazhar D. Management of febrile neutropenia in an acute oncology service. QJM Int J Med. 2012;105(4):327–336. doi:10.1093/qjmed/hcr217
- Lingaratnam S, Thursky KA, Slavin MA, Kirsa SW, Bennett CA, Worth LJ. The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian admitted episodes dataset. Intern Med J. 2011;41:121–129. doi:10.1111/j.1445-5994.2010.02343.x
- Mhaskar R, Clark OA, Lyman G, Botrel TE, Paladini LM, Djulbegovic B. Colony‐stimulating factors for chemotherapy‐induced neutropenic fever. Cochrane Database Syst Rev. 2014:CD003039. doi:10.1002/14651858.CD003039.pub2